$IVOB And The Female Condom: Two Peas In A Pod

It doesn’t take a rocket scientist to understand that IVOB’s INVOcell and FHCO’s Female Condom are intended for two different things; one to promote pregnancy, one to prevent it. The companies seem vastly different, diametrically opposed even. But the Dean implores his students to look closer… and discover the lucrative similarities.

IVOB and FHCO…

- Both started on the OTC Bulletin Board (with FHCO graduating to the AMEX and then recently the NASDAQ!)
- Both market innovative medical devices for women’s health that are inserted intra-vaginally
- Both received CE MARK approval for the EU and many other world markets first (with FHCO later receiving FDA approval!)
- Both have the same savvy Investor Relations company

In 2008, FHCO did $25 million in sales with a net income of nearly $5 million!

In order for IVOB to generate the same $25 million in sales, they would only need to attain approximately 57,000 patients out of the 150,000,000 infertile couples worldwide. That’s less than 1/30th of 1% (.00033333%) of the market.

With $25 million in sales, IVOB would have a $300 million market cap and $5-$6 price per share! … And that’s if they only reach 38 out of every 100,000 infertile women!

The numbers are staggering, to say the least, downright amazing if you consider those 50,000 patients amount to only 1% of the infertile couples in Pakistan. 1% of 1 country! IVOB is now selling in countries on 5 continents!

Forget “rocket scientist” – You don’t even need to pass 8th grade math to see the possibilities here! I want all my students to take a look at FHCO, take a look at IVOB … see if you don’t come to the same conclusions I have.

CollegeStock.com

*Never invest in a stock mentioned by The Dean unless you can afford to